Paula Ragan - 12 Feb 2024 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
President and CEO, Director
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Issuer symbol
XFOR
Transactions as of
12 Feb 2024
Transactions value $
-$21,892
Form type
4
Filing time
12 Feb 2024, 17:05:01 UTC
Previous filing
03 Nov 2023
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XFOR Common Stock Sale -$21.9K -21.7K -2.59% $1.01 815K 12 Feb 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023.
F2 Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.97 to $1.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.